Switch theme
Sign up to access all valuation multiples
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
2009
30
LTM Revenue n/a
LTM EBITDA -$54.8M
$51.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Regulus Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$54.8M.
In the most recent fiscal year, Regulus Therapeutics achieved revenue of n/a and an EBITDA of -$45.9M.
Regulus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Regulus Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$29.2M | -$45.9M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$28.3M | -$30.0M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Regulus Therapeutics's stock price is $2.
Regulus Therapeutics has current market cap of $127M, and EV of $51.0M.
See Regulus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $51.0M | $127M | XXX | XXX | XXX | XXX | $-0.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Regulus Therapeutics has market cap of $127M and EV of $51.0M.
Regulus Therapeutics's trades at n/a LTM EV/Revenue multiple, and -0.9x LTM EBITDA.
Analysts estimate Regulus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Regulus Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $51.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.1x | XXX | XXX | XXX |
| P/E | -2.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRegulus Therapeutics's NTM/LTM revenue growth is n/a
Regulus Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.7M for the same period.
Over next 12 months, Regulus Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Regulus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Regulus Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 57% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Regulus Therapeutics acquired XXX companies to date.
Last acquisition by Regulus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Regulus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Regulus Therapeutics founded? | Regulus Therapeutics was founded in 2009. |
| Where is Regulus Therapeutics headquartered? | Regulus Therapeutics is headquartered in United States of America. |
| How many employees does Regulus Therapeutics have? | As of today, Regulus Therapeutics has 30 employees. |
| Who is the CEO of Regulus Therapeutics? | Regulus Therapeutics's CEO is Mr. Joseph P. Hagan. |
| Is Regulus Therapeutics publicy listed? | Yes, Regulus Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Regulus Therapeutics? | Regulus Therapeutics trades under RGLS ticker. |
| When did Regulus Therapeutics go public? | Regulus Therapeutics went public in 2012. |
| Who are competitors of Regulus Therapeutics? | Similar companies to Regulus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Regulus Therapeutics? | Regulus Therapeutics's current market cap is $127M |
| What is the current EBITDA of Regulus Therapeutics? | Regulus Therapeutics's last 12-month EBITDA is -$54.8M. |
| What is the current EV/EBITDA multiple of Regulus Therapeutics? | Current EBITDA multiple of Regulus Therapeutics is -0.9x. |
| Is Regulus Therapeutics profitable? | Yes, Regulus Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
